Silvan Turkcan
Stock Analyst at Citizens JMP
(0.73)
# 3,950
Out of 5,000 analysts
8
Total ratings
37.5%
Success rate
-11.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Turkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics | Reiterated: Buy | $3 | $0.3711 | +708.41% | 1 | Aug 6, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $42 | $36.74 | +14.32% | 1 | Aug 6, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $80 | $55.70 | +43.63% | 1 | Jul 22, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $51 | $29.05 | +75.56% | 1 | Jul 20, 2026 | |
| CELC Celcuity | Reiterated: Buy | $160 → $177 | $79.37 | +123.01% | 3 | Jul 15, 2026 | |
| HURA TuHURA Biosciences | Initiated Coverage: Buy | $9 | $2.10 | +328.57% | 1 | Apr 27, 2026 |
Context Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $3
Current: $0.3711
Upside: +708.41%
IDEAYA Biosciences
Aug 6, 2026
Reiterated: Buy
Price Target: $42
Current: $36.74
Upside: +14.32%
CRISPR Therapeutics AG
Jul 22, 2026
Reiterated: Buy
Price Target: $80
Current: $55.70
Upside: +43.63%
Faeth Therapeutics
Jul 20, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $29.05
Upside: +75.56%
Celcuity
Jul 15, 2026
Reiterated: Buy
Price Target: $160 → $177
Current: $79.37
Upside: +123.01%
TuHURA Biosciences
Apr 27, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $2.10
Upside: +328.57%